DAXOR CORP Stock Price, News & Analysis

Daxor Corporation (Nasdaq: DXR) has successfully closed its underwritten public offering, issuing 210,527 shares at $9.50 per share, generating gross proceeds of approximately $2.1 million. The offering was slightly increased by the underwriter's partial exercise of an over-allotment option, which added 10,523 shares. Proceeds will be utilized for working capital, product development, capital expenditures, and potential acquisitions. The offering was conducted under an effective shelf registration statement filed with the SEC.

Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, has priced a public offering of 210,527 shares at $9.50 per share, aiming for gross proceeds of $2.0 million. The offering includes an additional option for underwriters to purchase up to 10,527 extra shares. The net proceeds will be allocated towards working capital, product development, and potential acquisitions. The offering is set to close on November 17, 2022, pending customary conditions.

Daxor Corporation (Nasdaq: DXR) announced an underwritten public offering of its common stock, with the lead underwriter Joseph Gunnar & Co., LLC. Daxor may offer an additional 15% of the shares sold, with proceeds intended for working capital, product development, acquisitions, and to repay outstanding debt. The offering's terms are subject to market conditions, and a preliminary prospectus is available through the SEC's website. The company has successfully conducted over 60,000 blood volume tests, showcasing its leadership in this medical field.

Daxor Corporation (Nasdaq: DXR) announces its BVA-100 diagnostic will be featured in a MedAxiom Academy webinar on November 17, 2022, focusing on best practices for blood volume analysis in heart failure. This collaboration aims to raise awareness among healthcare executives to improve heart failure outcomes, reduce costs, and enhance overall care quality. The BVA technology has demonstrated a significant reduction in heart failure readmissions and mortality rates. Registration for the free webinar is open to all.

Daxor Corporation (Nasdaq: DXR) announced a study published in the Journal of Cardiac Failure that highlights the effectiveness of its BVA-100 blood test for assessing heart failure. The study demonstrated that traditional surrogate markers fail to measure intravascular volume overload accurately, an essential factor in managing heart failure. The BVA-100 has shown a critical role in reducing hospital readmissions and improving patient outcomes for over 6 million Americans suffering from heart failure. CEO Michael Feldschuh emphasized the test's clinical importance in guiding treatment decisions.

Daxor Corporation (Nasdaq: DXR) will attend the American Heart Association Scientific Sessions from November 5-7, 2022, in Chicago, IL. This event gathers over 15,000 experts in cardiovascular research. The company emphasizes the effectiveness of its BVA guided treatment in heart failure, which can significantly lower 30-day readmissions by 56%, mortality by 82%, and hospital stays by 55%. Daxor's BVA-100® is the first FDA-cleared diagnostic blood test for quantifying blood volume, with over 60,000 tests conducted in leading U.S. hospitals.

Daxor Corporation (Nasdaq: DXR) announced a scientific debate titled "Debating Volume-based versus Pressure-based Methods and Devices to Measure Congestion in Heart Failure" at the Heart Failure Society of America Annual Scientific Meeting on October 3, 2022. Experts agreed that Daxor's BVA-100 blood test, the only FDA-cleared diagnostic for quantifying blood volume, is crucial for managing heart failure. The test has been conducted over 60,000 times in U.S. hospitals, demonstrating its clinical value in improving patient outcomes, including reduced mortality and readmissions.

Daxor Corporation (Nasdaq: DXR) will exhibit at the MedAxiom CV Transforum Fall’22 Conference in Austin, TX, from October 6-8, 2022. This conference gathers cardiovascular leaders to enhance patient care. Daxor's blood volume analysis (BVA) technology shows significant improvements in patient outcomes, including an 82% reduction in 30-day mortality. Daxor recently partnered with MedAxiom to promote BVA adoption among its clinical members. The company's innovations aim to optimize fluid management, enhancing healthcare delivery.

Daxor Corporation (Nasdaq: DXR) announced new findings from the Mayo Clinic at the Heart Failure Society of America meeting, revealing that over 50% of heart failure patients discharged from hospitals had suboptimal treatment based on BVA-100 blood tests. The study measured blood volume among 139 patients, showing persistent intravascular volume expansion post-discharge despite diuretic therapy. CEO Michael Feldschuh emphasized the urgency of blood volume analysis for improved patient outcomes, which could help reduce readmission rates penalized by the Centers for Medicare and Medicaid Services.